정보 및 인력의 교류 활성화를 통해 한국 과학의 경쟁력 확보를 지향합니다
Abstract
Liquid biopsies could transform how cancer is managed. By enabling serial, minimally-invasive analyses on tumor biomarkers (e.g., cell-free tumor DNA, extracellular vesicles, tumor cells), liquid biopsies could allow clinicians to detect cancers at their various stages, predict drug sensitivity, and even make informed treatment decision. Such potentials are increasingly demonstrated, and more emphasis is now placed on translating these concepts to clinical reality, through assay standardization, cross-platform validation, and scaled-up human studies. This presentation will highlight our recent advances in the liquid biopsy research. It will particularly focus on extracellular vesicles (EVs), nanoscale particles (50 – 200 nm in diameter) that carry molecular constituents of their originating cells. Two major topics will be discussed: i) platform development for EV detection and ii) clinical investigations that evaluated EVs’ clinical utility.